Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech develops pelareorep, an investigational systemically delivered immunotherapy for cancer that has been shown to activate innate immune-sensing pathways. Company news centers on pelareorep clinical and translational data, FDA interactions, and study activity across gastrointestinal and other solid tumor indications, including metastatic colorectal cancer, squamous cell anal carcinoma, pancreatic cancer, and breast cancer.
Recurring updates also cover the company's registration-focused development priorities, Fast Track Designation for pelareorep-based treatment in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, scientific meeting presentations, financing arrangements, and its completed change of jurisdiction to Nevada while ONCY common stock continues to trade on Nasdaq.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced promising preclinical data demonstrating that pelareorep can enhance the effectiveness of established anti-cancer agents, talazoparib and palbociclib. These findings were showcased at the AACR Annual Meeting 2021, where both combinations showed increased cancer cell apoptosis and improved tumor responses in murine models. Pelareorep exhibited synergy through immunological pathways, suggesting potential for broader therapeutic applications. The company aims to advance pelareorep in combination studies and is preparing for a pivotal phase 3 trial in metastatic breast cancer.
Oncolytics Biotech (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will participate in a panel discussion titled "Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma" at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Date: April 15, 2021, Time: 8:15 am ET.
Oncolytics is advancing its immuno-oncolytic virus, pelareorep, targeting various cancers. They are preparing for a Phase 3 registration study in metastatic breast cancer, exploring synergies with approved immuno-oncology therapies.
On April 5, 2021, Oncolytics Biotech announced a Key Opinion Leader (KOL) webinar for April 12, 2021, at 2:00 pm ET, focusing on AWARE-1 data concerning the immunotherapeutic effects of pelareorep in breast cancer and its synergy with CAR T cells. Key speakers include Dr. Aleix Prat from Hospital Clínic Barcelona and Dr. Richard Vile from the Mayo Clinic. The AWARE-1 study involves 38 patients and aims to evaluate pelareorep's efficacy. The company's management will also provide an update and be available for questions during the event.
Oncolytics Biotech (NASDAQ: ONCY) announced updated clinical data presentations from its AWARE-1 study on early-stage breast cancer and preclinical findings on pelareorep-based therapies. These will be shared at the AACR Annual Meeting on April 10-15, 2021. Key presentations include the AWARE-1 study's findings on pelareorep with atezolizumab and preclinical studies showing synergy with CDK4/6 inhibitors and talazoparib. The study's primary endpoint is CelTIL measurement, with 38 patients across five cohorts. Further details will be released post-abstract publication.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has initiated an at-the-market (ATM) equity offering agreement with Canaccord Genuity LLC, allowing the company to issue common shares up to US$80 million at prevailing market prices. This strategic move aims to enhance financial flexibility, facilitating ongoing business operations and clinical trials, while strengthening negotiation positions for potential agreements. Additionally, a Prospectus Supplement has been filed with relevant securities commissions to govern the offering, which will only take place in the U.S. through NASDAQ.
Oncolytics Biotech reported a financial overview and operational highlights for 2020, revealing a robust cash position with approximately $50 million on hand. Clinical data for pelareorep demonstrated significant potential in enhancing the efficacy of checkpoint inhibitors, particularly for HR+/HER2- breast cancer patients, evidenced by AWARE-1 trial results showing tumor PD-L1 expression increased by 105-fold. The company also advanced its BRACELET-1 and IRENE studies and plans to report further data in 2021, underpinning its strategy to address unmet medical needs.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call on March 5, 2021, at 8:30 am ET, to discuss its fourth quarter and full year 2020 financial results and corporate updates. Investors can access the call via dial-in and webcast, with a replay available post-call. The company focuses on the development of pelareorep, an immuno-oncolytic virus targeted at treating various cancers. Oncolytics is preparing for a phase 3 registration study in metastatic breast cancer and exploring additional studies in combination with other therapies.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced promising results from a preclinical study showcasing the enhanced effectiveness of pelareorep in combination with CAR T cell therapy for solid tumors. Conducted in collaboration with the Mayo Clinic, the study demonstrated a survival rate of 100% in mice treated with CAR T cells and pelareorep boosts. This combination overcame major limitations faced by CAR T therapies in solid tumors, leading to potential broadened applications in cancer treatment. The findings were presented at the CAR-TCR Summit Europe 2021.
Oncolytics Biotech announced significant findings from the AWARE-1 study at the San Antonio Breast Cancer Symposium, showing that pelareorep substantially increases the CelTIL score and PD-L1 expression in patients with early-stage breast cancer. Seventy-two percent of patients experienced increased CelTIL, while PD-L1 expression rose over 105-fold, enhancing the potential for immunotherapy. The study's results suggest pelareorep can synergize with checkpoint inhibitors, potentially improving treatment outcomes and expanding patient eligibility for these therapies.
Oncolytics Biotech (NASDAQ: ONCY) reported positive results from the ReoGlio phase 1b trial, assessing the combination of pelareorep and GM-CSF with standard chemoradiotherapy for glioblastoma multiforme patients. This trial demonstrated promising efficacy signals and confirmed safety with a median progression-free survival of approximately 8 months. The results were presented at the 2020 Society of Neuro-Oncology Annual Meeting, showing a median PFS of 9.4 months at a higher pelareorep dose. Oncolytics aims to advance pelareorep across various cancer indications while acknowledging the contributions of key partners.